STEK.US Stemtech Corporation
- Market cap
- USD 300K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is STEK.US undervalued?
Graham numberThe Graham number of Stemtech Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Stemtech Corporation fundamental analysis
No fundamental analysis for Stemtech Corporation yet.
Stemtech Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Stemtech Corporation
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. The company's products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood, and migrate them into tissues, where they can perform their daily function of renewal for optimal health. It offers its products under the RCM System,…
Full company profileStemtech Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Stemtech Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 6.62M | 4.38M | 4.32M | 4.56M | 4.92M | 5.05M | 2.88M | 2.18M |
| Gross Profit | -23.5K | -36.5K | -24.8K | -20.2K | 3.67M | 3.30M | 3.40M | 3.92M | 3.73M | 2.31M | 1.64M |
| Operating Income | -47.1K | -73.0K | -49.6K | -40.3K | -1.43M | -3.21M | -5.02M | -4.22M | -2.39M | -2.71M | -2.44M |
| EBITDA | -47.1K | -73.0K | -49.6K | -40.3K | -907K | -3.01M | -4.57M | 121K | -1.78M | -2.43M | -2.50M |
| Net Income | - | - | - | -33.8K | -1.73M | -15.3M | -8.63M | -5.43M | -3.77M | -4.05M | -3.09M |
| EPS | - | - | - | -0.06 | -3.20 | -0.41 | -0.19 | -0.05 | -0.03 | -0.01 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | - | 17.1K | 14.8K | 2.91K | 5.01M | 5.72M | 4.27M | 3.68M | 3.78M | 3.15M | 3.16M |
| Total Liabilities | - | 137K | 172K | 194K | 3.74M | 9.73M | 7.44M | 6.46M | 9.01M | 10.9M | 11.4M |
| Shareholders' Equity | - | -120K | -158K | -191K | 1.27M | -4.01M | -3.17M | -2.04M | -4.48M | -6.96M | -7.47M |
| Cash & Short-term Investments | - | 8.60K | 8.25K | 714.00 | 133K | 828K | 132K | 114K | 255K | 238K | 247K |
| Total Debt | - | 102K | 30.0K | 134K | 889K | 1.45M | 1.07M | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -37.6K | -24.8K | -25.4K | -11.4K | -267K | -1.91M | -1.22M | -2.04M | -601K | -484K | -961K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 45.2K | 11.6K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -37.6K | -24.8K | -25.4K | -56.6K | -278K | -1.91M | -1.22M | -2.04M | -601K | -484K | -961K |
| Ratios | |||||||||||
| ROE | - | - | - | - | -136.3% | - | - | - | - | - | - |
| ROA | - | - | - | -1,163.2% | -34.5% | -267.2% | -202.3% | -147.4% | -99.7% | -128.5% | -97.7% |
| Net Profit Margin | - | - | - | -0.5% | -39.4% | -353.7% | -189.3% | -110.3% | -74.6% | -140.7% | -141.5% |
| Debt to Equity | - | - | - | - | 0.70x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Stemtech Corporation dividends
Stemtech Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Aug 5, 2021.
Who owns Stemtech Corporation
- Insiders 8.30%
- Institutions 0.00%
- Public & others 91.71%
- Shares outstanding 3.00B
- Free float 2.74B
Stemtech Corporation company profile
- Company name
- Stemtech Corporation
- Ticker
- STEK.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 4851 Tamiami Trail North, Naples, FL, United States, 34103
- Phone
- 954 715 6000
- Website
- stemtech.com
About Stemtech Corporation
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. The company's products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood, and migrate them into tissues, where they can perform their daily function of renewal for optimal health. It offers its products under the RCM System, stemrelease3, and Stemflo MigraStem brands; oral health care under the OraStem brand; and rapid renew stem cell peptide night cream under the Collect One brand name, as well as Cellect One shield hypochlorous acid skin care products. It sells products through independent distributors. Stemtech Corporation was founded in 2005 and is headquartered in Naples, Florida.
Stemtech Corporation management
5- Mr. Charles S. ArnoldCEO & Director · born 1951
- Mr. John W. MeyerPresident, COO & Director · born 1955
- Ms. Shrilakshmi VadlapatlaChief Financial Officer · born 1985
- Mr. Tufan ObuzChief Administrative Officer · born 1970
- Mr. David E. Price Esq.Secretary · born 1965